Inhibitex shares soar: HCV candidate shows "impressive" synergy with ribavirin; key PII data awaited
This article was originally published in Scrip
Executive Summary
In recent weeks Inhibitex has been riding high on a wave of interest in public companies specialising in early-stage hepatitis C virus (HCV) treatments.